Related Experiment Video
Updated: May 4, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Achievement of LDL cholesterol targets in HIV-positive patients: a single center cohort study
Antonio Delle Cave1, Chiara Tognola2, Marco Bellomare1
1School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
Insights
Cardiovascular risk management in people living with HIV (PLWH) is challenging. Achieving LDL-C targets remains suboptimal, indicating a need for tailored prevention strategies for this population.
Area of Science:
- Cardiology
- Infectious Diseases
- Public Health
Background:
- People living with HIV (PLWH) have elevated cardiovascular (CV) risk due to chronic inflammation, ART, and traditional risk factors.
- Standard CV risk models often underestimate risk in PLWH.
- ART can have metabolic effects contributing to increased CV risk.
Purpose of the Study:
- To evaluate CV risk categories and LDL-C targets in PLWH.
- To assess the achievement rate of recommended LDL-C targets.
- To identify factors associated with LDL-C target achievement in PLWH on ART.
Main Methods:
- Retrospective analysis of 246 PLWH aged ≥40 on ART.
- Utilized electronic health records for clinical and laboratory data.
- Assessed 10-year CV risk using the SCORE2 model.
Main Results:
- Only 27.2% of PLWH achieved their LDL-C targets.
- Lower achievement rates were observed in high and very-high CV risk categories.
- Patients achieving targets had better CV profiles (lower LDL-C, SBP) but no significant relation to HIV-specific variables.
Conclusions:
- LDL-C target achievement is suboptimal in PLWH, suggesting inadequate CV risk control.
- Current strategies may not sufficiently address the CV risk burden in this population.
- More aggressive and HIV-tailored prevention strategies are needed for effective CV risk management.
Background And Aims:
People living with HIV (PLWH) face an increased CardioVascular (CV) risk due to the interaction between risk factors, chronic inflammation and AntiRetroviral Therapies (ART) metabolic effects. However, standard risk models often underestimate this burden. Our study aims to evaluate: (i) the CV risk category and the relative LDL-C targets; (ii) the achievement of these targets; and (iii) factors associated with target achievement and HIV-related variables.
Methods And Results:
A retrospective analysis was conducted on 246 PLWH, aged ≥40, on ART followed at the Niguarda Hospital. Clinical and laboratory data were extracted from the hospital's electronic registries and ten-year CV risk was assessed using SCORE2. Only 27.2% of the analyzed cohort achieved the recommended LDL-C targets with further lower prevalence in patients in the "high" or "very high" risk categories. Patients who achieved their LDL-C target had a more favorable cardiovascular risk profile (LDL-C: 75.8 ± 18.1 vs 121.1 ± 33.4 mg/dL, p < 0.001; systolic blood pressure: 116.9 ± 12.4 vs 123.4 ± 15.7 mmHg, p = 0.001), and CV risk categories, being less frequently classified as high and very-high risk (20.8 vs 52.4%, p < 0.0001). No significant relation was found between LDL-C target achievement and HIV-specific variables.
Conclusions:
LDL-C target achievement remains suboptimal and may not reflect adequate cardiovascular risk control in PLWH, supporting the need for more aggressive and HIV-tailored prevention strategies.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Retrovirus Life Cycles
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures
Bioavailability Study Design: Healthy Subjects Versus Patients

